Quarterly Results: Sharda Cropchem Ltd
Shital Jibhe / 04 Nov 2016

Sharda Cropchem Ltd., is currently trading at Rs. 411, up by 0.5 points or 0.12% from its earlier closing of Rs. 410.5 on the BSE. Revenue for the quarter marginally jumped by 3.8% yoy to Rs 247 cr.
Technical View:
Sharda Cropchem Ltd., is currently trading at Rs. 411, up by 0.5 points or 0.12% from its earlier closing of Rs. 410.5 on the BSE.
The scrip touched a high and low of Rs. 413 and Rs. 399 respectively, after opening at 410.5. Altogether 66029 (NSE+BSE) shares were traded on the counter; and the stock is currently trading below its 50 DMA.
Consolidated Results Q2FY17: (Rs. in crore)
***EBITDA margin change in bps
Sharda CropChem’s Q2FY17 numbers are a mixed bag as compared to Bloomberg estimates. Revenue has come in 8.5% lesser than the estimate of Rs 270 cr and net profit is 13.6% greater than the estimated figure of Rs 29 cr.
Revenue for the quarter marginally jumped by 3.8% yoy to Rs 247 cr.
Sharda CropChem's reported EBITDA has surged 24.1% yoy to Rs 51 cr while EBITDA margins have extended by 338 bps yoy to 20.6%. This can be attributed to adjustments for changes in inventories of finished goods & stock-in-trade increasing 121.3% yoy. Also, employee benefits expense and other expenses reduced by 5% and 15% yoy respectively further triggering margin expansion.
The company's net profit has jumped 25% yoy to Rs 33 cr.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.